Vor Biopharma
VOR
18.78
+0.47
+2.57%
Vor Biopharma
US · VOR
#3175 by market cap
Listed 2021
18.78
+0.47
+2.57%
Live - 5344 symbols - heartbeat 44s ago
· 2026-10-08 08:37
Pre-market
19.09
+1.65%
After-hours
18.78
0.00%
Overnight
18.80
+0.11%
- Market cap
- 1.11B
- P/E (TTM)i
- 1.63
- P/Bi
- -5.55
- EPSi
- -70.50
- Div yieldi
- 0.00%
- 52W posi
- 46%
Reader sentiment
Are you bullish or bearish on VOR?
Anonymous reader poll. Unscientific, not investment advice.
About Vor Biopharma
Vor Biopharma, Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. It is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.
- Founded
- 2015
- CEO
- Mr. Jean-Paul Kress, M.D.
- Employees
- 76
- Headquarters
- Boston, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- vorbio.com
Company profile
- Exchange
- US
- Symbol
- VOR
- Market-cap rank
- #3175
- Listing date
- 2021-02-05
- Market cap
- 1.11B
- Float cap
- 699.17M
- Shares out
- 59.16M
- Float shares
- 37.23M
Sectors & themes
Quote time 2026-10-08 08:37:46 · For reference only, not investment advice and not tailored to your situation.